Oncology and Hematology - Global Oncology Academy

401-416 of 651

Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
Project Oncology®
Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
Constance Lehman, MD, PhD
- Constance Lehman, MD, PhD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD; Sandy Srinivas, MD
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
Sandy Srinivas, MD
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
Ignacio Duran, MD; Wenxin Xu, MD
1.25 credits 10 episodes
- Ignacio Duran, MD
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 credits 10 episodes
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD; Wenxin Xu, MD
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Project Oncology®
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
The Potential Link Between COVID-19 and Cancer Regression
The Potential Link Between COVID-19 and Cancer Regression
Clinician's Roundtable
The Potential Link Between COVID-19 and Cancer Regression
Ankit Bharat, MD; Brian P. McDonough, MD, FAAFP
- Ankit Bharat, MD
- Brian P. McDonough, MD, FAAFP
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Project Oncology®
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Heather Greenlee, ND, PhD, MPH
- Heather Greenlee, ND, PhD, MPH
Understanding iMCD Through RNA Sequencing
Understanding iMCD Through RNA Sequencing
Project Oncology®
Understanding iMCD Through RNA Sequencing
Michael Gonzalez, PhD, MSc
- Michael Gonzalez, PhD, MSc
The Future of ITP Care: Exploring New Treatments
The Future of ITP Care: Exploring New Treatments
Project Oncology®
The Future of ITP Care: Exploring New Treatments
Michele Lambert, MD, MSTR
- Michele Lambert, MD, MSTR
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Project Oncology®
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Heather A. Parsons, MD, MPH
- Heather A. Parsons, MD, MPH
Diagnosing Castleman Disease: Key Considerations
Diagnosing Castleman Disease: Key Considerations
Project Oncology®
Diagnosing Castleman Disease: Key Considerations
Mateo Bustamante
- Mateo Bustamante
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Project Oncology®
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Joshua Brandstadter, MD, PhD, MSc
- Joshua Brandstadter, MD, PhD, MSc
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Insights from global key opinion leaders on optimizing patient care in NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit

26/11